Skip to main content

ORIGINAL RESEARCH article

Front. Public Health
Sec. Health Economics
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1415908
This article is part of the Research Topic Reviews in Public Health Expenditure and Performance View all 23 articles

Budget impact analysis of insulin glargine for patients with type 2 diabetes and severe hypoglycemia in Thailand

Provisionally accepted
Unchalee Permsuwan Unchalee Permsuwan 1,2*Chaicharn Deerochanawong Chaicharn Deerochanawong 3
  • 1 Chiang Mai University, Chiang Mai, Thailand
  • 2 Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Chiang Mai, Thailand
  • 3 Rajavithi Hospital, Bangkok, Thailand

The final, formatted version of the article will be published soon.

    Objective: The study aimed to assess the financial consequences of different adoption rates of insulin glargine (IGlar) instead of isophane protamine (NPH) insulin for patients with T2D and severe hypoglycemia in Thailand from the payer's perspective.The budget impact model over a 5-year period was used to estimate the net budget impact (NBI) of IGlar by comparing the total budget incurred under the scenario of NPH insulin only (scenario 1) and the scenario of IGlar entry (scenario 2). The total budget included either insulin costs or combination costs of insulin and severe hypoglycemia. Scenario 2 started at 20% uptake of IGlar and increased by 20% yearly. NBI was the difference in total budget of scenarios 2 and 1. NBI and oneway sensitivity analysis were analyzed.Results: Considering only insulin cost, IGlar treatment for patients with T2D patients and severe hypoglycemia incurred an average NBI of 174.9 million THB (5.1 million USD) yearly. When cost of severe hypoglycemia was included, total budget incurred from scenario 2 was less than that of scenario 1, yielding a negative NBI or cost savings.The NBI of IGlar entry would be substantial when considering only the insulin cost; however, the benefit of IGlar in terms of a lower rate of severe hypoglycemia compared with NPH insulin would clearly offset the additional cost of IGlar.

    Keywords: Budget impact analysis, Insulin glargine, NPH insulin, diabetes, Thailand

    Received: 11 Apr 2024; Accepted: 18 Dec 2024.

    Copyright: © 2024 Permsuwan and Deerochanawong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Unchalee Permsuwan, Chiang Mai University, Chiang Mai, Thailand

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.